Should You Pick PFE Stock At $25?
1. Pfizer's Q4 revenue of $17.8 billion exceeded estimates by $400 million. 2. Stock underperformed with -3% returns, while S&P500 gained 27% year-to-date. 3. Paxlovid sales rose significantly to $727 million, contrasting last year's $3.1 billion loss. 4. Pfizer's 2025 guidance indicates potential $1 billion sales hit due to Medicare changes. 5. Target cost-saving increased to $4.5 billion, enhancing profitability goals amid challenges.